GSK3B and major depressive disorder: Escitalopram has been demonstrated to enhance cognitive function in stressed rodent models by modulating the HPA axis and the insulin receptor substrate/Glycogen Synthase Kinase 3 (GSK-3β) signaling pathway (46), suggesting that escitalopram may represent a viable therapeutic strategy for the concurrent management of T2DM and MDD.